Last update 01 Nov 2024

OriCAR-017

Last update 01 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Autologous CAR-T

Synonyms

Chimeric antigen receptor (CAR)-T cell therapy targeting G protein-coupled receptor class-C group-5 member-D (GPRC5D)., GPRC5D-CAR-T, anti-GPCR5D CAR T-cell therapy(Origincell Therapeutics)

+ [2]

Target

GPRC5D

Mechanism

GPRC5D inhibitors(G-protein coupled receptor family C group 5member D inhibitors), Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsImmune System DiseasesCardiovascular Diseases+ [1]

Active Indication

Multiple Myeloma

Inactive Indication-

Originator Organization

OriCell Therapeutics Co.,Ltd.

Active Organization

OriCell Therapeutics Co.,Ltd.

Inactive Organization

Zhejiang University

Drug Highest PhasePhase 1/2

First Approval Date-

RegulationFast Track (US), Orphan Drug (US)

Clinical Trials associated with OriCAR-017

NCT06271252 / RecruitingPhase 1

A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.

The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma.
RIGEL Study

Start Date03 Apr 2024

Sponsor / Collaborator

OriCell Therapeutics Co.,Ltd.

CTR20232814 / RecruitingPhase 1/2

一项在复发难治多发性骨髓瘤受试者中评估OriCAR-017安全性、药代动力学和有效性的开放性、多中心临床研究（MERCURY）

[Translation] An open-label, multicenter clinical study to evaluate the safety, pharmacokinetics and efficacy of OriCAR-017 in subjects with relapsed or refractory multiple myeloma (MERCURY)

I期主要目的评估OriCAR-017治疗复发难治多发性骨髓瘤的安全性、耐受性和剂量限制性毒性；II期主要目的评估OriCAR-017治疗治疗复发难治多发性骨髓瘤的临床有效性

[Translation]

The main purpose of Phase I is to evaluate the safety, tolerability and dose-limiting toxicity of OriCAR-017 in the treatment of relapsed and refractory multiple myeloma; the main purpose of Phase II is to evaluate the clinical efficacy of OriCAR-017 in the treatment of relapsed and refractory multiple myeloma

Start Date28 Nov 2023

Sponsor / Collaborator

OriCell Therapeutics Co.,Ltd.

NCT06182696 / RecruitingPhase 1/2

An Open Label,Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Autologous T Cell Injection Targeting GPRC5D OriCAR-017 in Patients With Relapsed and/or Refractory Multiplemyeloma

An open label, dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of OriCAR-017 in R/RMM

Start Date26 Oct 2023

Sponsor / Collaborator

OriCell Therapeutics Co.,Ltd.

100 Clinical Results associated with OriCAR-017

100 Translational Medicine associated with OriCAR-017

100 Patents (Medical) associated with OriCAR-017

Literatures (Medical) associated with OriCAR-017

01 Feb 2023·The Lancet Haematology

GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial

Article

Author: Huang, He ; Zhang, Wei ; Kuang, Jiao ; Fu, Shan ; He, Xiaowen Peter ; Zhou, Linghui ; Huang, Simao ; Cui, Jiazhen ; Luo, Xueping ; Zhou, Xinkai ; Zhou, Jincai ; Ding, Xiaomin ; Zhang, Mingming ; Wang, Dongrui ; Chen, Siye ; Wei, Guoqing ; Tang, Yu ; Hu, Yongxian

BACKGROUNDChimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) has shown activity in treating relapsed or refractory multiple myeloma; however, relapse is still common, and new targets are needed. We aimed to assess the activity and safety profile of G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma.METHODSPOLARIS was a first-in-human, single-centre, single-arm, phase 1 trial of GPRC5D-targeted CAR T cells (OriCAR-017) done at the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. Eligible patients were adults aged 18-75 years with a diagnosis of relapsed or refractory multiple myeloma and an ECOG performance status of 0-2, had GPRC5D expression in bone marrow plasma cells greater than 20% or were positive for GPRC5D by immunohistochemistry, and had received at least three previous lines of treatment including proteasome inhibitors, immunomodulatory drugs, and chemotherapy. Patients were consecutively assigned to receive a single dose of intravenous OriCAR-017 at 1 × 10⁶ CAR T cells per kg, 3 × 10⁶ CAR T cells per kg, or 6 × 10⁶ CAR T cells per kg in the dose-escalation phase. In the expansion phase, patients received the recommended phase 2 dose. Recruitment to the expansion phase terminated early due to the COVID-19 pandemic on May 1, 2022. The primary endpoints were safety, the maximum tolerated dose and the recommended phase 2 dose. Safety and activity analyses included all patients who received OriCAR-017. This trial is registered with ClinicalTrials.gov, NCT05016778. This trial has been completed and is entering long-term follow-up.FINDINGSBetween June 9, 2021, and Feb 28, 2022, we recruited 13 patients for inclusion into the study. One patient was excluded because of GPRC5D negativity and two patients discontinued after apheresis because of rapid progression. Nine patients were assigned to the dose escalation phase (three received 1 × 10⁶ CAR T cells per kg, three received 3 × 10⁶ CAR T cells per kg, and three received 6 × 10⁶ CAR T cells per kg). The maximum tolerated dose was not identified, because no dose-limiting toxic effects were observed. On the basis of safety and preliminary activity, the recommended phase 2 dose was set at 3 × 10⁶ CAR T cells per kg, which was received by one additional patient in the dose expansion phase. Five patients (50%) were female, five (50%) were male, and all were Chinese. Five patients (50%) were previously treated with BCMA-targeted CAR T-cell therapy. Median follow-up was 238 days (IQR 182-307). There were no serious adverse events and no treatment-related deaths. The most common grade 3 or worse adverse events were haematological, including neutropenia (ten [100%] of ten patients), thrombocytopenia (nine [90%]), leukopenia (nine [90%]), and anaemia (seven [70%]). All patients had cytokine release syndrome (nine [90%] grade 1 and one [10%] grade 2). No neurological toxic effects were reported. Ten (100%) of ten patients had an overall response, of whom six (60%) had a stringent complete response and four (40%) had very good partial response. Two patients discontinued due to disease progression (one GPRC5D-positive patient in the middle-dose group and one GPRC5D-negative patient in the low-dose group).INTERPRETATIONThe results of this study suggest that GPRC5D is an active target for immunotherapy in multiple myeloma. GPRC5D-targeted CAR T-cell therapy is a promising treatment modality for patients with relapsed or refractory multiple myeloma and deserves further testing.FUNDINGOriCell Therapeutics.

Blood Cancer Journal

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

Review

Author: Bahlis, Nizar ; Pillarisetti, Kodandaram ; Masterson, Tara ; Rodriguez-Otero, Paula ; Hilder, Brandi ; Kane, Colleen ; Heuck, Christoph ; Renaud, Thomas ; Tolbert, Jaszianne ; Gray, Kathleen ; Verona, Raluca ; Cornax, Ingrid ; Moreau, Philippe ; Vishwamitra, Deeksha ; van de Donk, Niels W C J ; Chari, Ajai

AbstractMultiple myeloma is a genetically complex and heterogenous malignancy with a 5-year survival rate of approximately 60%. Despite advances in therapy, patients experience cycles of remission and relapse, with each successive line of therapy associated with poorer outcomes; therefore, therapies with different mechanisms of action against new myeloma antigens are needed. G protein–coupled receptor class C group 5 member D (GPRC5D) has emerged as a novel therapeutic target for the treatment of multiple myeloma. We review the biology and target validation of GPRC5D, and clinical data from early phase trials of GPRC5D-targeting bispecific antibodies, talquetamab and forimtamig, and chimeric antigen receptor T cell (CAR-T) therapies, MCARH109, OriCAR-017, and BMS-986393. In addition to adverse events (AEs) associated with T-cell–redirection therapies irrespective of target, a consistent pattern of dermatologic and oral AEs has been reported across several trials of GPRC5D-targeting bispecific antibodies, as well as rare cerebellar events with CAR-T therapy. Additional studies are needed to understand the underlying mechanisms involved in the development of skin- and oral-related toxicities. We review the strategies that have been used to manage these GPRC5D-related toxicities. Preliminary efficacy data showed overall response rates for GPRC5D-targeting T-cell–redirecting therapies were ≥64%; most responders achieved a very good partial response or better. Pharmacokinetics/pharmacodynamics showed that these therapies led to cytokine release and T-cell activation. In conclusion, results from early phase trials of GPRC5D-targeting T-cell–redirecting agents have shown promising efficacy and manageable safety profiles, including lower infection rates compared with B-cell maturation antigen- and Fc receptor-like protein 5-targeting bispecific antibodies. Further clinical trials, including those investigating GPRC5D-targeting T-cell–redirecting agents in combination with other anti-myeloma therapies and with different treatment modalities, may help to elucidate the future optimal treatment regimen and sequence for patients with multiple myeloma and improve survival outcomes.

News (Medical) associated with OriCAR-017

05 Jun 2024

·www.prnewswire.com

Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO Annual Meeting, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy

SHANGHAI and ROSELAND, N.J., June 5, 2024 /PRNewswire/ -- Oricell Therapeutics, a pioneering clinical-stage biopharmaceutical company, has presented the two-year long-term follow-up results of OriCAR-017, an open-label Phase I study evaluating GPRC5D-targeted CAR-T therapy in patients with relapsed/refractory multiple myeloma (RRMM), in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Efficacy & Durability of OriCAR-017 in RRMM Patients The updated data demonstrates that OriCAR-017 elicits deep and durable responses in RRMM patients as well as a favorable safety profile, including those refractory to anti-CD38 therapies, PIs, IMIDs, and those who have failed BCMA targeting CAR-T treatment. The long-term efficacy and safety follow-up results support OriCAR-017 as a promising therapeutic approach for RRMM. Currently, Oricell is smoothly advancing the clinical development of OriCAR-017 in both China (NCT06182696) and the United States (NCT06271252). As of January 16, 2024, all ten patients responded well to OriCAR-017, with the last patient having completed a 24-month follow-up. The overall response rate (ORR) was 100.0%, with a stringent complete response rate (sCR) of 80.0% and a very good partial response rate (VGPR) of 20.0%. All patients achieved 100% minimal residual disease negativity (MRD) at day 28, which was further confirmed as 100% negative at the 3-months follow-up. The median duration of response (mDoR) was 10.43 months (95% CI, 5.00-17.00), the median progression-free survival (mPFS) was 11.37 months (95% CI, 5.93-18.00), and the median overall survival (mOS) had not yet been reached (7 patients were still under survival follow-up, 1 patient died due to disease progression, and 2 patients died from COVID-19). In the high-dose group, where 67% of patients were previously treated with BCMA CAR-T, the mDoR was 17.23 months (95% CI, 7.33-NR), and the mPFS was 19.10 months (95% CI, 8.30-NR). Currently, a BCMA CAR-T-treated patient is still in remission (>24 months). Safety Profile of OriCAR-017 in the Treatment of RRMM The therapy was well-tolerated, with 9 out of 10 patients (90%) experiencing Grade 1 cytokine release syndrome (CRS) and only 1 patient (10%) experiencing Grade 2 CRS. No Grade 3 or higher CRS was observed. The median time to CRS onset was 2 days (range 1-9 days), with a median duration of 6 days (range 3-9 days). No immune effector cell-associated neurotoxicity syndrome (ICANS) or dose-limiting toxicities (DLTs) were observed. There were no serious adverse events (SAEs) or treatment-related deaths, cerebellar disorders, or delayed infections reported. Pharmacokinetics (PK) of OriCAR-017 in RRMM Patients There were no pharmacokinetic differences between dose levels, with a Cmax of 7354.7 copies/μL and an AUC0-28 of 68587 copies•day/μg. At high doses, CAR-T cells were still detectable at 9 months, and after 21 months of follow-up, one patient had CAR-T cell expansion above the lower limit of quantitation (LLOQ). Patients with Tlast ≥ 9 months had a longer PFS compared to those with Tlast < 9 months. G5 Expression in Response to OriCAR-017 Treatment in RRMM No correlation was observed between antigen expression and therapeutic efficacy. Baseline data from all patients showed positive GPRC5D expression in bone marrow CD138+ plasma cells (MMPC), while 50% of relapsed patients showed downregulated expression detected by flow cytometry. OriCAR-017 Demonstrates Significant Potential in Severely Progressed RRMM Patients It's worth noting that the study included patients with complex and advanced disease characteristics. Among the ten R/R MM patients, 40% had extramedullary disease (EMD), 50% had undergone one or more BCMA-directed CAR-T treatments, 70% had high-risk cytogenetics, 70% were classified as ECOG 2 score status, and 80% were at International Staging System (ISS) stages II & III. OriCAR-017 demonstrates its potential as a safe and efficacious treatment option for RRMM patients, marking a substantial progress in the fight against multiple myeloma and offering hope to those facing demanding health conditions. Details for the presentation as below: Oral Presentation #7511 Title: OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS). Session Type:Rapid Oral Abstract Session Session Title: Hematologic Malignancies—Plasma Cell Dyscrasia Link: About OriCAR-017 OriCAR-017, a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D, is a groundbreaking innovation in the treatment of relapsed/refractory multiple myeloma (RRMM). Leveraging Oricell Therapeutics' cutting-edge proprietary technology platforms, OriCAR-017 exhibits clearly differentiated binding avidity, persistence, anti-tumor efficacy and safety profile. OriCAR-017 received IND approval from FDA in Jan 2024 after its approval by NMPA in 2023. Impressive clinical results from the POLARIS study continue to be released. Currently, Oricell has assembled a skilled team to operate in both the U.S. and China, collaboratively accelerating pipeline development globally. SOURCE OriCell Therapeutics Co., Ltd.

Clinical ResultCell TherapyPhase 1ASCOImmunotherapy

29 Jan 2024

·www.biospace.com

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma.

SHANGHAI and ROSELAND, N.J., Jan. 29, 2024 /PRNewswire/ -- Oricell Therapeutics (Oricell), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for OriCAR-017 for patients with relapsed/refractory multiple myeloma (R/R MM). OriCAR-017 is a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D. The therapy leverages Oricell's proprietary platforms including Ori®Ab antibodies, Ori®CAR construct and unique CMC know-how to achieve optimal binding and superior persistence and anti-tumor efficacy out of rejuvenated CAR-T cells. The IND enables Oricell to initiate the clinical development for OriCAR-017 in the US immediately. The FDA IND approval for OriCAR-017 follows its NMPA IND approval in 2023 and the publication of clinical results from an Investigator Initiated Trial (POLARIS study) at the 2022 ASCO, 2022 EHA and The Lancet Haematology. The data showed that all ten patients with R/R MM responded to the therapy per IMWG criteria, achieving a 100% overall response rate (ORR), 80% stringent complete response. 100% minimal residual disease (MRD) negative rate was detected at day 28 and further confirmed at month 3. The therapy was well-tolerated, with no Immune effector cell-associated neurotoxicity syndrome (ICANS), no cerebellar disorder, no delayed infections, and only Grade 1/Grade 2 CRS that resolved rapidly. Of the ten R/R MM patients, 40% had extramedullary disease (EMD), 50% received prior BCMA CAR-T treatment(s), 70% had high-risk cytogenetics, and 70% with ECOG 2, 80% at ISS stage II & III. "The evidenced superior safety, efficacy and durability pro OriCAR-017 is truly exciting and will significantly benefit multiple myeloma patients on a global scale. Ten years' R&D cumulates not only OriCAR-017 but also the robust and integrated technology platforms that generate one-of-its-kind CAR-T products for liquid and solid tumors," said Peter He, Co-founder and Chief Scientific Officer of Oricell. "Exceptional teamwork is what Oricell relies upon. The fact that we were able to complete technical transfer from China to the U.S. in five months speaks for the standard of our teamwork." Helen Yang, Co-founder and Chief Executive Officer of Oricell further stated that, "With a great team and support from our stakeholders, we are confident in our ability to delivering best-in-class cell therapies to patients, providing them new hope and possibilities." About Oricell Therapeutics Oricell is a clinical-stage biotechnology company, dedicated to developing innovative cell therapies to address unmet medical needs in oncology and immunology around the world. Via Ori®Ab, Ori®CAR technology platforms and unique CMC know-how, Oricell has established unparalleled expertise in antibody screening and tuning, tumor immune microenvironment regulation, T cell infiltration, metabolism and killing ability. For more information, please visit: Forward-Looking Statements This press release contains "forward-looking statements" which are not historical facts, but instead are predictions about future events based on the beliefs as well as assumptions made by and information currently available to the management of Oricell Therapeutics Holdings Limited (the "Company" or "Oricell"). The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company, or industry results, to differ materially from any future results, performance or achievement implied by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date of this press release. The Company assumes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Cell TherapyImmunotherapyINDClinical Result

10 Aug 2023

·www.prnewswire.com

Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact

SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- August 10, 2023, in a groundbreaking development, Oricell Therapeutics Co., Ltd. ("Oricell") has received the green light for its Investigational New Drug (IND) application of OriCAR-017, a cutting-edge CAR-T cell therapy targeting GPRC5D to combat relapsed or refractory multiple myeloma (R/R MM). This remarkable milestone not only marks the world's first tier GPRC5D-targeting CAR-T therapy approved in China but also underlines Oricells prowess as a frontrunner in the biotech industry. About GPRC5D target GPRC5D, a G protein-coupled receptor that boasts high expression on multiple myeloma cells while maintaining low levels in normal tissues, has emerged as a promising therapeutic target for multiple myeloma. The revolutionary approach of independently targeting GPRC5D, regardless of BCMA expression levels, opens up new possibilities for patients who have exhausted conventional treatments or shown limited response to BCMA-targeting therapies. Earlier, data from the investigator initiated trial of OriCAR-017 (POLARIS) were presented at the 2022 ASCO (American Society of Clinical Oncology Annual Meeting) and the 2022 EHA (European Hematology Association Annual Meeting), attracting widespread attention due to its efficacy and safety advantages. The study enrolled 10 patients, included f ive patients who were previously treated with BCMA-targeted CAR T-cell therapy and four patients with extramedullary disease (EMD). According to the latest data, at a median follow-up time of 280 days (217 ~ 459 days), OriCAR-017 is turning heads with an impressive overall response rate (ORR) of 100% and a stringent complete response rate (sCR) of 80%. Additionally, compared to other therapies targeting the same antigen, OriCAR-017 demonstrated significant safety advantages, with only one case of grade 2 cytokine release syndrome (CRS) observed after treatment, while the rest were grade 1. Notably, no instances of immune effector cell-associated neurotoxicity syndrome (ICANS) and no grade 3 or higher skin toxicities or nail changes were reported, nor infection events were observed during long-term follow-up after treatment. Such reassuring safety data paves the way for reduced post-treatment clinical interventions, ultimately lightening the burden on healthcare providers and enhancing patient experiences. Oricell's Chairman and CEO, Helen Yang expressed, "OriCAR-017's approval as China's first and the world's leading GPRC5D-targeting CAR-T therapy is a pivotal moment for the biotech landscape. We are bridging the gap in late-line treatments for R/R MM, providing new hope to patients who have failed or responded poorly to different therapies targeting BCMA. The potential global impact of OriCAR-017 is undeniable, as we have been developing a global development plan for OriCAR-017 and are systematically advancing its registration for clinical trials in the United States. We have already obtained the 'Orphan Drug' designation from the Office of Orphan Products Development (OOPD) of the U.S. FDA." Helen is confident about the development prospects of this product and further stated, "with the IND clearance in China and seamless progress in overseas registrations and technology transfer, the stage is set for OriCAR-017 to become a game-changer in the fight against multiple myeloma. As Oricell continues to make strides in ground-breaking innovation, the future of cancer treatment looks more promising than ever before." SOURCE Oricell Therapeutics

ImmunotherapyCell TherapyOrphan DrugASCOClinical Study

100 Deals associated with OriCAR-017

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Myeloma	Phase 2	CN	OriCell Therapeutics Co.,Ltd.	26 Oct 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05016778 (POLARIS, ASCO2024) Manual	Phase 1	Relapse multiple myeloma \| Multiple Myeloma	10	OriCAR-017	(hisixykvyg) = ekbfrkrgry ezceklyjfr (kgxdpszjsx ) View more	Positive	24 May 2024
NCT05016778 (POLARIS, ASCO2024) Manual	Phase 1	Relapse multiple myeloma \| Multiple Myeloma	10	OriCAR-017	(hisixykvyg) = nxssobwowh ezceklyjfr (kgxdpszjsx ) View more	Positive	24 May 2024
NCT05016778 (POLARIS, Literature) Manual	Phase 1	Multiple Myeloma	13	OriCAR-017	(xaolncfass) = not identified cgglqxisqn (ofcakniezt ) View more	Positive	01 Feb 2024
NCT05016778 (POLARIS, PRNewswire) Manual	Early Phase 1	Relapse multiple myeloma	10	OriCAR-017	(zijhysfnic) = ylhleoxhuk delivmtqvl (cxtdixjmbl ) View more	Positive	30 Jan 2023
NCT05016778 (POLARIS, PRNewswire) Manual	Early Phase 1	Relapse multiple myeloma	10	OriCAR-017 (relapsed after BCMA CAR T-cell therapy)	(upvwaenrfk) = bszoeymxal dxsdvghzqn (qxncuajnyd ) View more	Positive	30 Jan 2023
NCT05016778 (POLARIS, ASCO2022) Manual	Phase 1	Relapse multiple myeloma \| Plasma cell myeloma refractory	11	OriCAR-017+Chemotherapy	(ykyjwavvzg) = The most common TEAEs were neutropenia (G3/4 100%), thrombocytopenia (G3/4 100%), leukopenia (G3/4 100%), lymphopenia (G3/4 100%) and anemia (G3/4 87.5%). oniimzuhys (cawqgamfui ) View more	Positive	02 Jun 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

OriCAR-017

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation